Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hansen Medical IDE

This article was originally published in The Gray Sheet

Executive Summary

Investigational device exemption study of Hansen Medical's Sensei X robotic catheter system and Artisan Control catheter for treatment of atrial fibrillation is approved by FDA, the Mountain View, Calif., company announces May 12. The ARTISAN AF pivotal trial is a prospective, randomized study of Sensei X for introducing and positioning Johnson & Johnson/Biosense Webster's Navistar Thermocool catheter in 300 patients with symptomatic, drug-refractory paroxysmal AF. Primary endpoints are absence of early onset of all major adverse events and freedom from AF through one year. Sensei X was first approved by FDA last fall (1"The Gray Sheet" Sept. 28, 2009)

You may also be interested in...

Hansen Medical's Sensei X

Firm's "next generation" robotic coronary catheter system gains FDA market go-ahead, the firm announces Sept. 15. The device supports the new Artisan Extend control catheter, which "increases the reachability and navigation properties of the existing Artisan catheter by offering more than 20% improvement in both bend and reach," the company claims. Shipments will begin in the third quarter. In addition, Hansen's Lynx robotic irrigated ablation catheter, also supported by the Sensei X platform, will debut in Europe in the first half of 2010, pending CE mark approval, the company notes. Hansen's original Sensei robotic catheter system was cleared in 2007 for manipulation and control of electrophysiology mapping catheters (1"The Gray Sheet" May 14, 2007)

Coronavirus Notebook: US FDA's Paper Push, Industry Exes/US Officials Emphasize Their Collaboration

Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.

Good News For Immunomedics' Triple Negative Breast Cancer Trial

A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts